Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of

On August 13, 2021, in a decision that largely flew under antitrust and patent practitioners' radars, U.S. District Judge Lucy H. Koh mostly denied a motion to dismiss in the alleged "reverse payment" case...

Related Keywords

Nate Raymond ,Lucyh Koh ,Brooke Grp ,Amgen ,While The Court ,Us Senate ,Jazz Pharmaceuticals ,Actavis Inc ,Gilead Scis Inc ,Reuters ,Supreme Court ,Intl Medication Sys Ltd ,Belcher Pharm ,Judge Lucy ,Hatch Waxman Act ,Judge Koh ,Favored Entry ,Third Circuit ,Generic Defendant ,Ninth Circuit ,Antitrust Litig ,Namenda Indirect Purchaser Antitrust ,Sensipar Cinacalcet Hydrochloride ,Tablets Antitrust Litig ,Williamson Tobacco ,Medication Sys ,Actos End Payor Antitrust Litig ,Mondaq ,Xryem Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of Quot Profit Crushing Competition ,Anti Trust Competition Law ,Antitrust ,U Competition ,Litigation ,Ediation Amp Arbitration ,Trials Amp Appeals Compensation , ,